WESTBURY, NY, US - Sep 24, 2018 - BioIVT, a leading provider of research models and services for drug development, today announced that it will be hosting the 2018 HEPATOPAC User Group Meeting (UGM) from 8:30 a.m. to 4:30 p.m. ET on Oct. 18 in Boston, MA.

BioIVT added Hepregen’s HEPATOPAC Technology to its portfolio of products and services for metabolism and toxicology evaluations when it acquired Ascendance Biotechnology, Inc. in March 2018.

During the UGM, researchers will discuss how they have employed HEPATOPAC cultures to investigate the ADME-Tox profiles of drug candidates and assess the efficacy of new drugs in their lead selection programs. The program features speakers from IONIS Pharmaceuticals, the University of North Carolina, Chapel Hill, Vertex Pharmaceuticals Inc., Roche Pharmaceutical, Merck & Co, Inc., and BioIVT. Attendees will also have the opportunity to network with their peers and discuss potential collaborations.

HEPATOPAC Technology is used to create stable in vitro liver models that enable long-term hepatic metabolism and toxicity studies. HEPATOPAC cultures, formed using a proprietary patterning method, consist of hepatocyte “islands” surrounded with supportive stromal cells. This specialized architecture replicates the physiological microenvironment of the liver. Hepatocytes remain healthy and viable in the HEPATOPAC platform and demonstrate physiologically-relevant function and metabolic activity for up to four weeks.

Interested parties can view the HEPATOPAC UGM agenda and register for this complimentary event at https://info.bioivt.com/hepatopac-user-event-2018.

About BioIVT

BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.